Skip to content

Immunovant, Inc. IMVT Earnings yield

Earnings yield at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
3.6%-1.9pp
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-4.4%-1.5pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-10.8%-2.6pp
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-1.7%-3.6pp
Summit Therapeutics logo
Summit TherapeuticsSMMT
-8.2%-11.1pp
TG Therapeutics logo
TG TherapeuticsTGTX
8.7%+8.1pp

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Calculated from Immunovant, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s earnings yield?
Immunovant, Inc. (IMVT) reported earnings yield of -10% in Q1 2026.
How has Immunovant, Inc.'s earnings yield changed year-over-year?
Immunovant, Inc.'s earnings yield increased by 29.8% year-over-year, from -14.3% to -10%.
What is the long-term trend for Immunovant, Inc.'s earnings yield?
Over 5 years (2021 to 2026), Immunovant, Inc.'s earnings yield has grown at a 7.9% compound annual growth rate (CAGR), from -6.8% to -10%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.